CD47 and anemia: Thus, anti-CD47 mAb can trigger antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) towards normal cells in an Fc receptor-dependent manner, posing concerns for on-target adverse events such as anemia and thrombocytopenia.